PERSPECTA

News from every angle

← Back to headlines

Clearmind and SciSparc Collaboration Advances MDMA-Related IP for PTSD Treatment

The collaboration between NeuroThera-Clearmind and SciSparc is advancing MDMA-N-acylethanolamines intellectual property for treating PTSD, supported by increasing U.S. federal interest in psychedelic innovation.

24 Aug, 12:51 — 24 Aug, 12:51
PostShare

Sources

Showing 1 of 1 sources
taiwan-newsMostly Factual14h ago

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - Taiwan News

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation  Taiwan News

Read full article →

Related Stories

Exploring Mental Health and Wellness Beyond Traditional Therapy, Including Sound Therapy

3h ago

Health Company Admits Maradona Test Mix-Up in Death Trial

4h ago

FDA Clears Roche and Eli Lilly's Alzheimer's Blood Test

6h ago

Cardiologist highlights key food for lowering cholesterol

7h ago